Literature DB >> 32573785

Multi-omics analysis reveals the functional transcription and potential translation of enhancers.

Yingcheng Wu1,2, Yang Yang3, Hongyan Gu4, Baorui Tao1, Erhao Zhang1, Jinhuan Wei1, Zhou Wang5, Aifen Liu1, Rong Sun1, Miaomiao Chen1, Yihui Fan1,6, Renfang Mao1,2.   

Abstract

Enhancer can transcribe RNAs, however, most of them were neglected in traditional RNA-seq analysis workflow. Here, we developed a Pipeline for Enhancer Transcription (PET, http://fun-science.club/PET) for quantifying enhancer RNAs (eRNAs) from RNA-seq. By applying this pipeline on lung cancer samples and cell lines, we showed that the transcribed enhancers are enriched with histone marks and transcription factor motifs (JUNB, Hand1-Tcf3 and GATA4). By training a machine learning model, we demonstrate that enhancers can predict prognosis better than their nearby genes. Integrating the Hi-C, ChIP-seq and RNA-seq data, we observe that transcribed enhancers associate with cancer hallmarks or oncogenes, among which LcsMYC-1 (Lung cancer-specific MYC eRNA-1) potentially supports MYC expression. Surprisingly, a significant proportion of transcribed enhancers contain small protein-coding open reading frames (sORFs) and can be translated into microproteins. Our study provides a computational method for eRNA quantification and deepens our understandings of the DNA, RNA and protein nature of enhancers.
© 2020 UICC.

Entities:  

Keywords:  eRNA pipeline; enhancer RNA; sORF; transcription factor

Mesh:

Substances:

Year:  2020        PMID: 32573785     DOI: 10.1002/ijc.33132

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment.

Authors:  Yu Shen; Ying C Wu; Lixiong Gu
Journal:  Ann Transl Med       Date:  2020-11

2.  Integrating the Epigenome and Transcriptome of Hepatocellular Carcinoma to Identify Systematic Enhancer Aberrations and Establish an Aberrant Enhancer-Related Prognostic Signature.

Authors:  Peng Huang; Bin Zhang; Junsheng Zhao; Ming D Li
Journal:  Front Cell Dev Biol       Date:  2022-03-01

3.  Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.

Authors:  Xiaoyun Bu; Shuang Liu; Dongsheng Wen; Anna Kan; Yujie Xu; Xuanjia Lin; Ming Shi
Journal:  Mol Ther Oncolytics       Date:  2022-07-06       Impact factor: 6.311

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.